Wen-ping Li

No. 139 Ziqiang Road
Shijiazhuang, 050051, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Updated studies on the immunotherapy of prostate cancer

Updated studies on the immunotherapy of prostate cancer

Journal: Zhonghua nan ke xue = National journal of andrology
Published: April 01, 2022

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.

Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: February 17, 2016

Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.

Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: December 20, 2015

Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Journal: Oncotarget
Published: December 04, 2015

Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: September 26, 2015

Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: December 09, 2014

Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.

Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.

Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: August 04, 2014

Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.

Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.

Journal: The Journal of international medical research
Published: July 13, 2014

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR
Published: January 01, 2014

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.

Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.

Journal: The Journal of international medical research
Published: April 10, 2013
Showing 1-10 of 10

Last Updated: 09/26/2026